Shankus Pharma Private Limited - Due diligence report

A 360° intelligence report on Shankus Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and …

2021-11-23 Mehsana, Gujarat Active Unlisted Active Compliant
Share
Connect MCP
SP Shankus Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Shankus Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
83/100
Trust Score
Low Risk

Shankus Pharma Private Limited is assessed as Low Risk with a Trust Score of 83/100. Shankus Pharma Private Limited is an active private limited indian non-government company incorporated in 2021, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 09 Aug 2026 from the latest processed filings. Shankus Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
92/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 3 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Profitable - internal accruals available.

Charges position: 5 open (52.54 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India3 48.0 cr
Hdfc Bank Limited2 48.0 cr
Compliance Score: 92/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Delayed payments to MSME suppliers disclosed (2 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 85/100
NameDIN / PANDesignationAppointedTenureDIN status
JAGDISH MADHAVLAL CHAUDHARY 01234567 Director 01/04/2018 6 yrs Approved
DILIP SHANKARBHAI CHAUDHARY 01234567 Director 01/04/2018 6 yrs Approved
Nysa Dilip Chaudhary 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
3
Capital events
0 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Priosh Pharma Chem Ag Subsidiary Company 74.00%
Neovant Therapeutics Private Limited Associate Company 74.00%
Clinoquent Research Private Limited Associate Company 74.00%
Zasya Life Sciences Private Limited Associate Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 80 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 2 year(s).
Profit expanded 2.1x year-on-year.
Young company (4 years).
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
5 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 5,222.00.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment66/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 5 open charge(s) of 52.54 cr already registered.
  • Compliance record supports lending.
Investor view79/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 13 events
30 Sep 2025
Last AGM held
Annual general meeting
15 Jul 2025
Director appointed
Nysa Dilip Chaudhary (Additional Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
31 Mar 2024
Share transfer (FY 2024)
17000.00000000 shares to RAKESHKUMAR KESHAVLAL CHAUDHARY
29 Dec 2023
Director ceased
ANAND RAKESHBHAI CHAUDHARY
26 Dec 2023
Charge created
State Bank Of India - 1.95 cr
04 Dec 2023
Charge created
Hdfc Bank Limited - 15.00 cr
30 Aug 2022
Charge created
State Bank Of India - 25.00 cr
30 Mar 2022
Charge created
State Bank Of India - 10.48 cr
12 Jan 2022
Charge created
Hdfc Bank Limited - 11.30 Lakh
23 Nov 2021
Incorporated
Registered with Roc Ahmedabad
Director appointed
JAGDISH MADHAVLAL CHAUDHARY (Director)
Director appointed
DILIP SHANKARBHAI CHAUDHARY (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 2 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
2 overseas direct investment(s) (ODI) on record - international footprint.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Vital Therapeutics And Formulations Private Limited U24239TG2004PTC042735 Hyderabad, Telangana, India
Yashraj Biotechnology U73100MH1999PLC119769 Navi Mumbai, Maharashtra, India
Synergy Poly Additives Private Limited U25209HP2001PTC024553 Himachal Pradesh, Himachal Pradesh, India
Millenium Cement Company Private Limited U26922WB1999PTC088899 Jalpaiguri, West Bengal, India
Lark Laboratories U24230DL1979PLC009548 New Delhi, Delhi, India
Brichem Sciences U24304GJ2016PTC094569 Ahmedabad, Gujarat, India
Mepromax Life Sciences Private Limited U24231GJ2005PTC045918 Wadhwan, Gujarat, India
Brooks Laboratories L24232HP2002PLC000267 Nalagarh, Himachal Pradesh, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Shankus Pharma Private Limited before audits and certifications: compliance score 92/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Shankus Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Shankus Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Shankus Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Shankus Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Shankus Pharma Private Limited an active company?

Shankus Pharma Private Limited has MCA status “Active” with a compliance score of 92/100 (Low Risk).

Is Shankus Pharma Private Limited financially healthy?

Shankus Pharma Private Limited has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.

Should I do business with Shankus Pharma Private Limited?

Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Shankus Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Shankus Pharma Private Limited have loans or charges against its assets?

5 open charge(s) are registered against its assets.

Is Shankus Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 92/100 (Low Risk).

Is it risky to lend to Shankus Pharma Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.